Trifluridina [INN-Spanish] en es it fr

Trifluridina [INN-Spanish] Brand names, Trifluridina [INN-Spanish] Analogs

Trifluridina [INN-Spanish] Brand Names Mixture

  • No information avaliable

Trifluridina [INN-Spanish] Chemical_Formula


Trifluridina [INN-Spanish] RX_link

Trifluridina [INN-Spanish] fda sheet

Trifluridina_[INN-Spanish] FDA

Trifluridina [INN-Spanish] msds (material safety sheet)

Trifluridina [INN-Spanish] Synthesis Reference

No information avaliable

Trifluridina [INN-Spanish] Molecular Weight

718.794 g/mol

Trifluridina [INN-Spanish] Melting Point

No information avaliable

Trifluridina [INN-Spanish] H2O Solubility

No information avaliable

Trifluridina [INN-Spanish] State


Trifluridina [INN-Spanish] LogP


Trifluridina [INN-Spanish] Dosage Forms

Powder for solution to be mixed for injection (2mg verteporfin/mL reconstituted verteporfin)

Trifluridina [INN-Spanish] Indication

For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

Trifluridina [INN-Spanish] Pharmacology

Verteporfin, otherwise known as benzoporphyrin derivative, is a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Trifluridina [INN-Spanish] Absorption

No information avaliable

Trifluridina [INN-Spanish] side effects and Toxicity

Overdose of drug and/or light in the treated eye may result in nonperfusion of normal retinal vessels with the possibility of severe decrease in vision that could be permanent. An overdose of drug will also result in the prolongation of the period during which the patient remains photosensitive to bright light.

Trifluridina [INN-Spanish] Patient Information

Trifluridina [INN-Spanish] Organisms Affected

Humans and other mammals